Skip to main content

Table 3 Characteristics of morphology before or after HSCT

From: Evaluation of erythroblast macrophage protein related to erythroblastic islands in patients with hematopoietic stem cell transplantation

Groups

Peripheral blood

Bone marrow

MWBCs (×109/L)

MERw (%)

MMCs (×109/L)

MERm (%)

BMHD

MIQAS

MMCs (×109/L)

MERm (%)

The first control

5.7 ± 1.3

1.1 ± 0.4

2.7 ± 1.5

1.4 ± 0.5

Activity

21.4 ± 4.5

12.8 ± 2.5

48 ± 4.3

The second control

2.1 ± 0.7

6 ± 1.2

1.7 ± 0.6

10.3 ± 1.7

Low or extremely low

3.2 ± 1.4a

5.3 ± 1.4a

16.7 ± 1.6a

30 days after HSCT

2.5 ± 1.0a

13.6 ± 1.6a

1.5 ± 0.4

17.8 ± 1.9a

Activity

43.3 ± 4.1a,b

6.6 ± 1.7a

23.5 ± 1.2a

90 days after HSCT

3.2 ± 1.2a

15.4 ± 1.8a

2.2 ± 0.7

19.7 ± 1.4a

More activity

46.2 ± 3.6a,b

10.4 ± 1.5a

31.2 ± 1.8a

180 days after HSCT

3.0 ± 1.1a

14.2 ± 1.5a

2.1 ± 0.8

18.5 ± 1.6a

Activity

44.7 ± 4.2a,b

8.8 ± 1.2a

33.4 ± 1.1a

  1. aP < 0.05, vs. the first control group.
  2. bP < 0.05, vs. the second control group.
  3. BMHD, Bone marrow hyperplastic degree; MERm, mean erythroblastic cells of ratio in mononuclear cells; MERw, Mean erythroblastic cells of ratio in white blood cells; MIQAS, Mean islands quantity in a smear; MMCs, mean mononuclear cells; MWBCs,Mean white blood cells.